Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Taxes (2024 - 2025)

Adma Biologics' Current Taxes history spans 2 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Current Taxes rose 147.52% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $8.6 million, up 147.52%, while the annual FY2025 figure was $8.6 million, 147.52% up from the prior year.
  • Current Taxes reached $8.6 million in Q4 2025 per ADMA's latest filing, up from $2.8 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $8.6 million in Q4 2025 to a low of $2.7 million in Q2 2025.